G protein-coupled receptor modulation with pepducins: Moving closer to the clinic

Annals of the New York Academy of Sciences

Volumn 1226, Issue 1, 2011, Pages 34-49

  Dimond, Patricia ^a   Carlson, Kenneth ^b   Bouvier, Michel ^c   Gerard, Craig ^d   Xu, Lei ^e   Covic, Lidija ^f   Agarwal, Anika ^f   Ernst, Oliver P ^g   Janz, Jay M ^b   Schwartz, Thue W ^h   Gardella, Thomas J ⁱ   Milligan, Graeme ^j   Kuliopulos, Athan ^f   Sakmar, Thomas P ^k   Hunt Iii, Stephen W ^b  

^a BioInsight Communications   (United States)

^b Anchor Therapeutics Inc   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k ROCKEFELLER UNIVERSITY   (United States)

more..

Author keywords

Allosteric modulation; G protein coupled receptors; Meeting report; Pepducins; Transmembrane signaling

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; CASPOFUNGIN; CHEMOKINE RECEPTOR CXCR4; DAPTOMYCIN; G PROTEIN COUPLED RECEPTOR; LIPOPEPTIDE; LIRAGLUTIDE; MATRIGEL; METALLOPROTEINASE; PEPDUCIN; UNCLASSIFIED DRUG;

ASTHMA; BIOLUMINESCENCE; CANCER THERAPY; CONFERENCE PAPER; DIABETES MELLITUS; HOST RESISTANCE; HUMAN; HYPERTENSION; LIGAND BINDING; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PATHOPHYSIOLOGY; PHARMACOPHORE; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 79957553894     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06039.x     Document Type: Conference Paper

References (46)

1. Miller, J., A. Agarwal, L.A. Devi, K. Fontanini, J.A. Hamilton, J-P. Pin, D.C. Shields, C.A. Spek, T.P. Sakmar, A. Kuliopulos & S.W. Hunt III. 2009. Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann. N.Y. Acad. Sci. 1180 S1: E1-12.
2. Covic, L., A.L. Gresser, J. Talavera, et al 2002. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA 99: 643-648.
3. Strader, C.D., T.M. Fong, M.R. Tota, et al 1994. Structure and function of G protein-coupled receptors. Annu. Rev. Biochem. 63: 101-132.
4. Dalman, H.M. & R.R. Neubig 1991. Two peptides from the alpha 2A-adrenergic receptor alter receptor G protein coupling by distinct mechanisms. J. Biol. Chem. 266: 11025-11029.
5. Kjelsberg, M.A., S. Cotecchia, J. Ostrowski, et al 1992. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol. Chem. 267: 1430-1433.
6. Covic, L., M. Misra, J. Badar, et al 2002. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8: 1161-1165.
7. Kaneider, N.C., A. Agarwal, A.J. Leger & A. Kuliopulos 2005. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat. Med. 11: 661-665.
8. Sakmar, T.P. 2005. Twenty years of the magnificent seven. With decades of discovery on seven transmembrane receptors, why haven't we saved the day? The Scientist 19: 22.
9. Shpakov, A. 2009. Polycationic peptides as nonhormonal regulators of chemosignal systems. J. Evol. Biochem. Physiol. 45: 431.
10. Remsberg, J.R., H. Lou, S.G. Tarasov, et al 2007. Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. J. Med. Chem. 50: 4534-4538.
11. Tchernychev, B. et al 2010. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc. Natl. Acad. Sci. USA 107: 22255-22259.
12. Angers, S. et al 2000. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. USA 97: 3684-3689.
13. Gales, C. et al 2006. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat. Struct. Mol. Biol. 13: 778-786.
14. Audet, M., M. Lagace, D.W. Silversides & M. Bouvier 2010. Protein-protein interactions monitored in cells from transgenic mice using bioluminescence resonance energy transfer. FASEB J. 24: 2829-2838.
15. Gerard, C. & N.P. Gerard 1994. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12: 775-808.
16. Humbles, A.A. et al 2000. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406: 998-1001.
17. Scola, A.M., K.O. Johswich, B.P. Morgan, et al 2009. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol. Immunol. 46: 1149-1162.
18. Bamberg, C.E. et al 2010. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 285: 7633-7644.
19. Yona, S., H.H. Lin, W.O. Siu, et al 2008. Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem. Sci. 33: 491-500.
20. Xu, L., S. Begum, J.D. Hearn & R.O. Hynes 2006. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 103: 9023-9028.
21. Xu, L. & R.O. Hynes 2007. GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment. Cell Cycle 6: 160-165.
22. Xu, L. et al 2010. GPR56 plays varying roles in endogenous cancer progression. Clin. Exp. Metastasis 27: 241-249.
23. Li, S. et al 2008. GPR56 regulates pial basement membrane integrity and cortical lamination. J. Neurosci. 28: 5817-5826.
24. Granovsky-Grisaru, S. et al 2006. The pattern of protease activated receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol. Oncol. 103: 802-806.
25. Ghio, P. et al 2006. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. Clin. Lung Cancer 7: 395-400.
26. Boire, A. et al 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313.
27. Yang, E. et al 2009. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cell and suppresses tumor survival and metastasis Cancer Res. 69: 6223.
28. Agarwal, A. et al 2008. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 7: 2746-2757.
29. Merritt, W.M. et al 2008. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100: 359-372.
30. Agarwal, A. et al 2010. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res. 70: 5880-5890.
31. Paez-Ribes, M. et al 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
32. Hofmann, K.P. et al 2009. A G protein-coupled receptor at work: the rhodopsin model. Trends Biochem. Sci. 34: 540-552.
33. Scheerer, P. et al 2008. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-502.
34. Schwartz, T.W. & W.L. Hubbell 2008. Structural biology: a moving story of receptors. Nature 455: 473-474.
35. Engelstoft, M.S., K.L. Egerod, B. Holst & T.W. Schwartz 2008. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab. 8: 447-449.
36. Solomon, C.G. & R.G. Dluhy 2004. Bariatric surgery-quick fix or long-term solution? N. Engl. J. Med. 351: 2751-2753.
37. Buchwald, H. et al 2009. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122: 248-256.
38. Samuel, B.S. et al 2008. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl. Acad. Sci. USA 105: 16767-16772.
39. Holst, B. et al 2009. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. Endocrinology 150: 2577-2585.
40. Dean, T. et al 2006. Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol. Endocrinol. 20: 931-943.
41. Ferrandon, S. et al 2009. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat. Chem. Biol. 5: 734-742.
42. Okazaki, M. et al 2008. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc. Natl. Acad. Sci. USA 105: 16525-16530.
43. Jenkins, L. et al 2010. Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of beta-arrestin-2 and activate Galpha13. Biochem. J. 432: 451-459.
44. Milligan, G. 2011. Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol. Sci. Mar 8. [Epub ahead of print.
45. Jenkins, L. et al 2010. Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Galpha and beta-arrestin-2. Br. J. Pharmacol. 162: 733-748.
46. Yang, Y. et al 2010. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86: 1-5.